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In the present study, we compared the dynamics and composition of microtubules in cell lines derived from the human breast
adenocarcinoma MCF-7 containing either the wild-type p53 (wt-p53; MN1) or a dominant-negative variant of p53 gene
(mut-p53; MDD2). Mut-p53 cells were significantly resistant to the cytotoxicity of the microtubule-targeted drugs (vinca alkaloids
and taxanes), as compared with wt-p53 cells. Studies by high-resolution time-lapse fluorescence microscopy in living cells indicated
that the dynamics of microtubules of mut-p53 cells were altered in complex ways and were significantly increased as compared
with microtubules in wt-p53 cells. The percentage of time microtubules spent in growing and shortening phases
increased significantly, their catastrophe frequency increased, and their overall dynamicity increased by 33%. In contrast, their
shortening rate and the mean length shortened decreased. Cells containing mut-p53 displayed increased polymerisation of
tubulin, increased protein levels of the class IV b-tubulin isotype, STOP and survivin, and reduced protein levels of class II b-tubulin
isotype, MAP4 and FHIT. We conclude that p53 protein may contribute to the regulation of microtubule composition and function,
and that alterations in p53 function may generate complex microtubule-associated mechanisms of resistance to tubulin-binding
agents.
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The effect of p53 tumour suppressor gene status on sensitivity to
microtubule-targeted drugs has been a subject of controversy, and
may be different whether one considers normal or neoplastic cells
(Wahl et al, 1996; McGill and Fisher, 1997; Brown and Wouters,
1999). In cancer cells, alterations of the p53 tumour suppressor
gene confer resistance to microtubule-targeted drugs (Wu and
El-Diery, 1996; Galmarini et al, 2001). We recently reported
that chemoresistance present in p53-deficient cells might be
attributed to defective apoptotic pathways (Galmarini et al,
2001). However, p53 also associates with microtubules in vitro
and in vivo (Giannakakou et al, 2000b), and has been reported
to regulate negatively the putative microtubule-stabilising
protein microtubule-associated protein 4 (MAP4), the microtu-
bule-related inhibitor of apoptosis survivin (Mirza et al, 2002), and
the microtubule-destabilising protein stathmin/OP18 (Johnsen
et al, 2000; Murphy et al, 1999). Whether these interactions of
p53 with the microtubule network directly affect microtubule
composition and dynamics thus favouring drug resistance is not
known.
The dynamic behaviour of microtubules includes dynamic
instability, in which the ends of the microtubule undergo frequent
episodes of slow growing and rapid shortening, as well as
treadmilling, which is the net addition of tubulin at one end of a
microtubule and net loss at the other end. Both phenomena are
important for cell cycle progress as they play critical roles in the
assembly and function of the mitotic spindle and cytokinesis
(Margolis and Wilson, 1998; Rodionov et al, 1999).
Specifically, highly dynamic microtubules are required for the
proper attachment of chromosomes to the spindle and for the
complex movements of the chromosomes (called ‘congression’),
including their proper alignment at metaphase and chromosome
separation at anaphase. Failure of the microtubules to capture all
the chromosomes at prometaphase, as well as the absence of
tension on the chromosomal kinetochores during metaphase, leads
to mitotic block (Rudner and Murray, 1996) and apoptosis (Jordan
et al, 1996).
Recent studies have indicated that microtubule-targeted drugs
(e.g. vinblastine, paclitaxel) block mitosis at the metaphase/
anaphase transition by suppressing dynamic instability and
treadmilling (Yvon et al, 1999; Goncalves et al, 2001). Moreover,
changes in the composition and dynamics of microtubules appear
to contribute to specific resistance to microtubule-targeted drugs
(reviewed in Dumontet and Sikic, 1999).
In this study, we used cell lines derived from the human breast
adenocarcinoma MCF-7 containing either wild type (wt)-p53 or a
dominant-negative variant of the p53 gene (previously shown to be
resistant to microtubule-targeted drugs, Galmarini et al, 2001),
as a model to investigate the possible relation between p53
expression, dynamics and composition of microtubules and drug
resistance. Revised 5 February 2003; accepted 13 March 2003
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sMATERIAL AND METHODS
Reagents
Antibodies against acetylated tubulin (6-11B-1), tyrosinated
tubulin (Tub-1A2), b-tubulin (Tub 2. 1), g-tubulin, tau (Tau-2),
MAP2 (HM-2), MAP1b/MAP5 (AA6) and b-actin (AC-15) were
purchased from Sigma (St Quentin Fallavier, France); antibodies
against class IV b-tubulin isotype were purchased from Biogenex
(San Ramon, CA, USA). Antibodies against class II (7B9 clone) and
class III b-tubulin isotype (TUJ1 clone) were generously provided
by Anthony Frankfurter (University of Virginia, Charlottesville,
VA, USA), against STOP (23.5) and glutamylated tubulin (L7) by
Didier Job (Grenoble, France); against MAP4 by Chloe ´ Bulinski
(New York). Peroxidase-conjugated secondary antibodies were
from Covalab (Oullins, France), enhanced chemiluminiscence
Western blot detection reagents from Amersham ECL system
(Amersham Corp., Buckinghamshire, UK). Vinblastine was
provided by Lilly Laboratories (Saint Cloud, France), paclitaxel
by Bristol-Myers Squibb (Paris, France).
Cell lines
The wt-p53-containing MN-1 cell line and the MDD2 cell line,
derived from the human breast carcinoma cell line MCF-7, were
provided by Moshe Oren (Weizmann Institute of Science, Israel).
The MDD2 subline is an isogenic variant obtained from MCF-7 by
transfection with a dominant-negative mutant (pCMV-DD-p53)
coding for a p53miniprotein containing the first 11 residues and
residues 302–390 of mouse p53 (Shaulian et al, 1992). MN1 cells
were obtained by transfection of the MCF-7 line with the empty
plasmid. HCT116 p53 /  is a cell line derived from colorectal
carcinoma in which two promoterless targeting vectors were used
to disrupt sequentially the two p53 alleles (Bunz et al, 1998). All
cell lines were cultured as previously described (Galmarini et al,
2001).
We have previously shown that MDD2 cells displayed 31.5-fold
resistance to paclitaxel (MN-1 IC50: 7.6nM; MDD2 IC50: 240nM)
and 50-fold resistance to vinblastine (MN-1 IC50: 6.8nM; MDD2
IC50: 340nM) in comparison with MN-1 cells (Galmarini et al,
2001).
Dynamics measurements
Microinjection of labelled tubulin, image acquisition and dynamic
measurements were performed as previously described (Goncalves
et al, 2001). Bovine brain tubulin was labelled with carboxyrho-
damine succinimidyl ester (Molecular Probes, Inc., Cergy, France)
according to Hyman (1991). Cells were seeded at low density 2–3
days prior to microinjection on gridded glass coverslips (Eppen-
dorf Scientific, Inc., LEPECQ, France). Injections were performed
on a Zeiss Telaval 31 inverted microscope using a  40 phase
objective lens, and an Eppendorf Transjector 5246 and Injectman
microinjection system. Following injections, cells were incubated
for 4–6h prior to analysis to allow for incorporation of
rhodamine-tubulin into microtubules. Microinjected cells were
visualised on a Nikon Eclipse E800 fluorescence microscope using
a 1.4 N.A.100  plan apochromatic lens at 36.570.51C. The
positions of the plus-ends of individual microtubules in the
peripheral lamellar region of cells were tracked over time using the
MetaMorph track points program (Universal Imaging, Westche-
ster, PA, USA), transferred to a Microsoft Excel spreadsheet and
graphed as position vs time to generate a ‘life-history plot’ for each
microtubule using Real Time Measurement software (a kind gift
from E Gliksman and E Salmon). From these graphs, growth and
shortening rates and durations were derived by regression
analysis. A difference of 40.5mm between any two consecutive
points was considered as a growth or shortening event.
Transitions into microtubule depolymerisation or shortening
are termed catastrophes, and transitions from shortening to
growth or pause are called rescue. The catastrophe frequencies
per unit time and per length grown were calculated by dividing the
number of transitions from growth and pause to shortening by
either the sum of the time in growth and pause or the sum of the
distance grown, respectively. Similarly, time and length-based
rescue frequencies were determined by dividing the number of
transitions from shortening to growth or pause by the time spent
or the distance shortened. Dynamicity is a measure of total tubulin
exchange at the end of a microtubule and was calculated by
dividing the sum of the total length grown and shortened by the
lifespan of the microtubule.
Reverse transcriptase–polymerase chain reaction
The level of mRNA expression of b-tubulin, g-tubulin and STOP
was assessed by semiquantitative reverse transciptase–polymerase
chain reaction (rt–PCR) in a Perkin Elmer 9600 thermal cycler as
previously described (Dumontet et al, 1999). After standardisation
using ribosomal 18S primers, the PCR products of the genes of
interest were produced at 35 cycles (PCR profile: denaturation at
941C for 10s, annealing at 561C for 3s, and elongation at 721C for
30s). Primer sequences and the number of cycles were as follows:
b-tubulin: forward: ATGAGGGAAATCGTG; reverse: AGTGGGT-
CAGCTGGAAGC; g-tubulin: forward: AGTTGGCCAACTTCATCC;
reverse: TGCCCCAGGAGATGTAGT; STOP: forward: GAG-
CAGCTCCTACAGGAATGA; reverse: TGAAGGGTTCDCTGTA-
GAGG. The PCR products were then separated by electro-
phoresis on a 6% polyacrylamide gel and visualised by staining
with ethidium bromide. All samples were analysed in three
separate experiments.
Western blots
Protein expression was determined by Western blot analysis in
MN-1 and MDD2 cells at basal conditions as described previously
(Galmarini et al, 2001). Horizontal scanning densitometry was
performed on Western blots by acquisition into Adobe Photo Shop
(Apple, Cupertino, CA, USA) and analysis by the Kodak Digital
Science 1D image analysis software.
Evaluation of total polymerised and soluble tubulin
Cells in pellets were lysed by resuspension in 100ml of low-salt
buffer (20mM Tris-HCl pH 6.8; 1mM MgCl2;2 m M EGTA) for
5min at 371C in the dark, then centrifuged at 14000r.p.m. for
10min at room temperature. The resultant supernatants, contain-
ing the soluble tubulin fraction, were transferred to a separate
centrifuge tube and kept on ice. The pellets, containing
polymerised tubulin, were resuspended in Ling’s buffer (10mM
Tris pH 7.5, 1.5mM MgCl2 and 10mM KCl) in a volume equal to
that of the supernatants. Protein extracted from MN-1 cells
(100mg) and from MDD2 cells (300mg) were loaded onto a 12%
acrylamide–SDS gel, then processed for immunoblotting with a
pan-b-tubulin antibody as described above. The results were
expressed as the ratio of polymerised/soluble tubulin for each cell
line.
Luciferase assays
One million HCT116 /  p53 /  cells were cotransfected with
325ng of the pGL-3-STOP-luc plasmid containing the entire STOP
promoter coupled to luciferase (generously given by E Denarier,
Grenoble, France) and 50ng of the pCMV-wt-p53 plasmid
containing the complete coding sequence of wt-p53, using
lipofectine (GibcoBRL, Cergy, France). Cells were harvested in
reporter lysis buffer (Promega, Charbonnierbs, France) 48h after
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stransfection, and luciferase activity was quantified with a
luminometer. Representative results of triplicate measurements
of duplicate experiments with mean and standard deviation are
shown in the figures. As a positive control, HCT1116 p53 /  cells
were cotransfected with the pGL-3-p21/Waf1-luc plasmid and the
pCMV-wt-p53 plasmid. Samples were analysed in three separate
experiments
RESULTS
Microtubule dynamics in living cells expressing wt
or mutated p53
The dynamic behaviour of microtubules in MDD2 cells is
illustrated in a time-lapse sequence (Figure 1A). Microtubules
alternated between phases of growing, shortening, and a pause
state (a state of attenuated dynamic activity). The dynamic
behaviour of single microtubule in living MN1 and MDD2 cells
is graphed in Figure 1B in what are known as ‘life-history plots’,
which shows the changes in length of single microtubules over
time. The life-history plots of a number of microtubules were used
to determine the parameters of dynamic instability (Tables 1
and 2).
The dynamics of microtubules in mut-p53 cells were altered in
significant and complex ways from those in the wt-p53 cells
(Tables 1 and 2 and Figure 1). Changes in several parameters of
microtubule dynamics indicated that the dynamics of micro-
tubules in mut-p53 cell microtubules were significantly increased.
The microtubules of mut-p53 cells spent less time in pause (62% in
wt-p53 vs 43% in mut-p53 cells), with a correspondingly greater
fraction of time spent in growing or shortening. Their catastrophe
frequency per minute was increased significantly, by 43% (Table 2),
which is consistent with and may account for the 29% reduction in
the duration of pause events. The mean length shortened was
reduced by 33% (from 5.2 to 3.5mm). The frequency of rescue
based on length shortened was increased by 47% (Table 2), which
is consistent with and may account for the decrease in shortening
length. Overall, their dynamicity increased by 33%. Interestingly,
in one way their dynamics were clearly suppressed, that is, their
shortening rate was reduced by 25% (from 29.172.8 to
21.771.7mmmin
 1). The net result of these changes was that
microtubules in mut-p53 cells underwent brief episodes of short-
length changes. That is, relatively frequent catastrophes occurred
during which they lost relatively little polymer length as a result of
the slowed shortening rates. These changes are likely to deter
significantly the proper formation of a mitotic spindle.
Analysis of microtubule protein content at basal condition
By Western blotting of total cell extracts, we found that the total
b-tubulin protein content was decreased in mut-p53 cells
(Figure 2A). Analysis of total b-tubulin mRNA levels by rt–PCR
using pan-b primers also showed higher levels in wt-p53 cells
(Figure 2A), confirming that b-tubulin expression was down-
regulated in the mut-p53 cells and suggesting that regulation of
tubulin levels was transcriptional.
The ratio of polymerised tubulin to soluble tubulin was
determined by Western blotting and densitometry. We found that
it required larger amounts of protein from MDD2 cells to obtain
sufficient signal to determine the ratio of polymer/soluble tubulin
than from MN1 cells; the reasons for this difference are not known,
but it appears that tubulin is less abundant overall in the mut-p53
cells than in the wt cells. The results also suggest that the ratio of
polymerised tubulin to soluble tubulin was slightly higher in mut-
p53 (2.3) than in wt-p53 cells (1.5) (Figure 2A).
In the MDD2 cells, the amount of Class IV b-tubulin was greatly
increased, by seven-fold (Figure 2B), whereas Classes I and II were
reduced and Class III was unchanged in comparison with wt-p53-
containing MN-1 cells. Post-translational modifications of
a-tubulin were different between mut-p53 and wt p53 cells with
higher contents of tyrosinated, acetylated and glutamylated tubulin
protein in the mut-p53 cells (Figure 2B).
We then analysed the content of centriolar and centromeric
proteins. Mut-p53 cells expressed more g-tubulin mRNA and
protein than MN-1 cells (Figure 3A), indicating centrosome
amplification in MDD2 cells. This is in accordance with our
previous studies demonstrating that MDD2 cells, but not MN-1
cells, were tetraploid (DI¼1.93) (Galmarini et al, 2001).
Analysis of microtubule-associated proteins at basal
condition
In the mut-p53 cells at basal conditions, STOP mRNA and protein
were more abundant (Figure 3A), whereas MAP4 protein was
decreased slightly (Figure 3B). Tau protein, MAP1b, and MAP2
were not expressed in either cell line (data not shown). Expression
of the tumour suppressor protein FHIT (which binds tubulin)
(Chaudhuri et al, 1999) was reduced in mut-p53 cells, whereas
expression of the mitotic microtubule-associated antiapoptotic
protein survivin (Li et al, 1998) was greatly increased (Figure 3B).
Bim, a Bcl-2 family member reported to interact with microtubules
(Strasser et al, 2000), was expressed at similar levels in both the cell
lines (Figure 3B).
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Figure 1 (A) Dynamic behaviour of microtubules in living MN1 cells.
Arrows indicate a microtubule that undergoes a growing event. Time is
indicated in seconds. (B) Life-history plots of single microtubule from living
MN1 and MDD2 cells.
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sp53 inactivates the transcription of the STOP gene
in reporter gene assays
As shown in Figure 3C, STOP protein was expressed higher in
HCT116 p53 /  than in HCT116 p53þ/þ cells. Luciferase assays
showed that STOP promoter activity was inhibited by 55% by
cotransfection of the pGL-3-STOP-luc with wt-p53 (pCMV-wt-p53)
in HCT116 p53 null cells in comparison with the control plasmid
(pGL3 control) (Figure 3C). HCT1116 p53 /  cells cotransfected
with the pGL-3-p21/Waf1-luc plasmid and the pCMV-wt-p53
plasmid showed an increase of 38% of p21/Waf1 promoter activity
(data not shown).
DISCUSSION
Our results show that dynamic instability of microtubules of
mut-p53 cells was significantly increased as compared with that of
their parental wt-p53 counterparts. The microtubule catastrophe
frequency per minute was increased significantly, and micro-
tubules spent more time in growing and shortening. They spent
less time in pause and the pauses were shorter in duration. Their
overall dynamics (dynamicity) were increased by 33%. However,
the increase in overall dynamics in mut-p53 cells is only part of the
picture, as in these cells the shortening rate was significantly
decreased and the rescue frequency per length shortened was
increased. As a result, the mean shortening length of the
microtubules was reduced by 33%. The net result was that
mut-p53 microtubules underwent frequent short excursions of
shortening, but they lacked extensive changes in length as
observed in wt-p53 microtubules.
Complex alterations in microtubule dynamics such as those
which we have observed in mut-p53 cells may be involved in
mechanisms of resistance to microtubule-targeted drugs. Recently
published data showed that excessively rapid microtubule
dynamics as well as suppressed dynamics were associated with
resistance to paclitaxel in a human lung cancer line (Goncalves
et al, 2001). One possibility is that different microtubules in the
mitotic spindle, in particular, microtubules bound to kinetochores
and interpolar microtubules, differ in terms of dynamic require-
ments. The complexity of the mitotic spindle requires fine tuning
of the dynamics of all microtubules for proper function.
Mut-p53 cells also displayed a variety of alterations in
microtubule protein composition that may be involved in the
changes in microtubule dynamics. Although total tubulin content
was slightly decreased in mut-p53 cells, the fraction of polymerised
tubulin was higher. This change may result from the altered
dynamics, from differences in microtubule stabilising protein
content or function, or from alterations in some other undeter-
mined factor regulating tubulin polymerisation. Post-translational
alterations in a-tubulin, such as acetylation and detyrosination,
have been preferentially found in microtubules with long half-lives,
but it is not clear whether these modifications directly increase
the lifespan of microtubules or simply accumulate as a result
of prolonged existence of microtubule structures. The latter
Table 1 Parameters of dynamic instability in MN1 and MDD2 cells
Parameters MN1 (wt-p53) MDD2 (mut-p53) Percentage of change
a
Mean rate (mmmin
 1)
Growth 8.670.9
b 8.970.8 +1
Shortening 29.172.8 21.771.7*  25
Mean duration (min)
Growth 0.2970.03 0.3270.04 +6
Shortening 0.1870.02 0.1670.01 0
Attenuation 0.5170.04 0.3570.03*  29
Mean length change/event (mm)
Growth 2.5 2.8 +12
Shortening 5.2 3.5  33
Percentage time spent
Growth 25.4 39.7 +56
Shortening 12.8 17.1 +34
Attenuation 61.8 43.2  30
Dynamicity (mmmin
 1) 5.9 7.9 +33
*Po0.02; estimates of significance by Student’s t-test.
aThe percentage difference relative to the corresponding parameter between
MDD2 cells and MN1 cells. Parameters of dynamic stability were determined by measurement of at least 31 microtubules from
seven to 12 cells for each cell type.
bs.e.m.
Table 2 Transition frequencies in MN1 and MDD2 cells
Transition frequency MN1 (wt-p53) MDD2 (mut-p53) Percentage of change
a
Eventsmin
 1
Catastrophe 0.8470.12 1.270.2 +43%
Rescue 4.270.7 4.470.6 +5%
Eventsmm
 1
Catastrophe 0.4270.06 0.4070.05  5%
Rescue 0.1570.03 0.2270.03 +47%
aThe percentage difference in MDD2 cells relative to the corresponding behavioural parameter in MN1 cells.
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shypothesis would be compatible with the larger degree of
acetylation and detyrosination observed in mut-p53 cells, since
the microtubules in these cells undergo reduced shortening events,
and thus are longer-lived than those in wt-p53 cells.
We also observed that the relative proportion of Class IV was
greatly increased (seven-fold), whereas the proportions of classes I
and II were reduced in mut-p53 cells. The b-tubulin isotype
composition of microtubules in vitro can alter their dynamic
properties (Panda et al, 1994; Derry et al, 1997), suggesting that the
differences we observed in isotype composition between wt-p53
and mut-p53 cells may contribute to the observed differences in
dynamics. These alterations may also be involved in drug
resistance to microtubule-targeted drugs (Burkhart et al, 2001).
The greatly increased expression of Class IV b-tubulin we observed
would be predicted to result in increased resistance to paclitaxel
(Derry et al, 1997), just as we observed for the mut-p53 cells.
The stabilising protein STOP and its corresponding mRNA were
found to be much more highly expressed in the mut-p53 cells than
in the wt-p53 cells, suggesting negative transcriptional regulation
of STOP by p53 protein. This negative regulation was confirmed by
a luciferase assay in HCT116 p53-null cells. The effects of STOP on
microtubule dynamic instability are not known. However, STOP is
an important factor in determining resistance of microtubules to
cold-induced depolymerisation (Guillaud et al, 1998), and thus it
may affect microtubule dynamics and could potentially contribute
to higher polymerised tubulin content and/or to the reduced rate
and extent of MT depolymerisation in mut p53 cells.
Microtuble-associated protein 4 is often assumed to stabilise
microtubules. Other studies have found that expression of p53
downregulates expression of MAP4 (Murphy et al, 1996; Zhang
et al, 1998). In contrast, we observed reduced expression of MAP4
in the mut-p53 cells, in conjunction with increased dynamic
instability. Thus, our results are consistent with the predicted
microtubule-stabilising capacity for MAP4. Although there is
insufficient information available to predict the effects of changes
in MAPs on microtubule dynamics with confidence, the fact that
several MAPs that potentially affect microtubule stability are
transcriptionally regulated by p53 strongly supports the role of p53
in regulating microtubule dynamics.
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Figure 2 Comparisons of microtubule components between MN1
(wt-p53) and MDD2 (mut-p53) cells by Western blot at baseline. (A) Beta:
b-tubulin; Actin: b-actin; Pol: polymerised b-tubulin; Sol: soluble b-tubulin;
for Pol and Sol, the results shown are expressed as percentage of total
tubulin. (B)T y r :t y r o s i n a t e da-tubulin; Ac: acetylated a-tubulin; Glu: glutamy-
lated a-tubulin; I: class I b-tubulin; II: class II b-tubulin; III: class III b-tubulin;
IV: class IV b-tubulin; Actin: b-actin. These figures represent one of the
two (A) or three (B) experiments performed.
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Figure 3 (A) Rt–PCR and Western blot analysis of g-tubulin and STOP
in MN1 (wt-p53) and MDD2 cells (mut-p53); (B) Western blot analysis of
proteins interacting with microtubules; (C) Western blot analysis of STOP
protein in HCT116 p53þ/þ and p53 /  cells and negative regulation of
the STOP promoter by wt-p53 in HCT1116  /  colorectal cells. (A) and
(B) represent one of the three experiments performed. Surv: survivin;
Actin: b-actin. For (C), HCT116 p53-null colorectal cancer cells were
cotransfected with the pGL-3-STOP-luciferase plasmid and pCMV-wt-p53
plasmid. Basic, pGL-3 basic plasmid; control, pGL-3 control plasmid;
STOPþe, cotransfection of pGL-3-STOP-luciferase plasmid and empty
pCMV; STOPþp53, cotransfection of pGL-3-STOP-luciferase plasmid and
pCMV-wt-p53.
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sSurvivin, an inhibitor of apoptosis associated with microtubules
of the mitotic spindles, was found to be much more highly
expressed in the mut-p53 cells than in the wt-p53 cells. Both
overexpression of survivin and loss of wt-p53 expression have
been detected in many tumours and this was associated with drug
resistance (Altieri, 2001; Mirza et al, 2002). Overexpression of
survivin influences microtubule dynamics and stabilisation of
microtubules by directly regulating growth/catastrophe rates or via
recruitment of MAPs or motor proteins participating in spindle
dynamics (Giodini et al, 2002). In this context, overexpression of
survivin related to the presence of mut-p53 cells may promote
resistance to microtubule-targeted drugs by influencing micro-
tubule dynamics and by inhibiting apoptosis.
Although we have previously reported that chemoresistance
present in p53-deficient cells might be attributed to defective
apoptotic pathways (Galmarini et al, 2001), alterations in
microtubule composition and dynamics observed in mut-p53 cells
might also contribute to the resistant phenotype. Our data indicate
that p53 protein is involved in the structural and functional
integrity of the microtubular cytoskeleton in complex and diverse
ways. However, we cannot exclude that alterations in microtubular
network observed in MDD2 cells were also because of genetic drift
over time; chromosomal aberrations were present in the mut-p53
as demonstrated by the tetraploidy (Galmarini et al, 2001) and
centrosome amplification observed in these cells. Different studies
have demonstrated that the loss of p53 function leads to genetic
instability allowing cells to accumulate mutations in many genes,
including b-tubulin mutations (Giannakakou et al, 1997, 2000a).
Silencing of p53 may thus predispose MDD2 cells to accumulate
b-tubulin alterations that would alter microtubule composition
and dynamics conferring resistance to microtuble-targeted drugs.
In summary, our results indicate that alterations in microtubule
composition and dynamics observed in the presence of a
dominant-negative p53 protein are likely to participate in
microtubule-mediated mechanisms of resistance to microtubule-
targeted drugs. This resistance may therefore result both from
deficient apoptotic pathways and from modifications in micro-
tubules and their associated proteins, thus reducing the sensitivity
of intracellular targets to these compounds.
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